Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024
NK:IO, a London startup developing a cell therapy for treating solid tumors, has announced the appointment of a permant chief executive and the finalization of a seed funding round. 2 October 2024
Halda Therapeutics, a US biotech company advancing cancer treatments, announced the appointment of Christian Schade as president and chief executive. 1 October 2024
Nxera Pharma has entered a new commercial partnership agreement with fellow Japanese drugmaker Shionogi regarding the distribution and sales for Quviviq (daridorexant 25 and 50mg) in Japan. 1 October 2024
AstronauTx, a biotech developing novel treatments for Alzheimer's disease and other neurodegenerative disorders, has announced the appointment of Jane Rhodes as chief executive officer. 1 October 2024
Privately-held German pain specialist Grünenthal has appointed Jan Adams its new chief commercial officer (CCO) and a member of the corporate executive board. 30 September 2024
USA-based engineered regulatory T cells (Tregs) company GentiBio today announced the appointment of Dr Mark Bach as chief medical officer. 30 September 2024
Acadia Pharmaceuticals has appointed Catherine Owen Adams to succeed Steve Davis as chief executive (CEO) and a member of its board of directors. 28 September 2024
Recently-created by US biotech incubator Flagship Pioneering, Abiologics has announced the appointment of Maria-Chiara Magnone as its chief scientific officer. 26 September 2024
German privately-held biotech ARTCLINE Bio-Therapies today announced the appointment of Dirk Hessel as additional managing director of the company. 23 September 2024
Stalicla, a privately-held Swiss biotech, today announced that Dr Paulo Fontoura will be joining its drug development team as chief scientific and clinical development advisor. 19 September 2024
US contract development and manufacturing organization (CDMO) BioCentriq has appointed Syed Husain as its new chief executive (CEO), and as a member of the board of directors. 19 September 2024
Structure Therapeutics, a specialist in small molecule treatments for metabolic and pulmonary diseases, has announced key leadership appointments. 18 September 2024
Californian biopharma 89bio, a company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, has announced an important appointment. 17 September 2024
British biotech IMU Biosciences has announced key changes to its leadership team as it looks to grow in the field of precision medicine. 17 September 2024
Ohio, USA-based Trailhead Biosystems has appointed Josh Snow as its new chief commercial officer, as the company moves to expand its presence in the commercial market with its iPSC-derived human cell products. 16 September 2024
Under pressure from certain shareholders, autoimmune diseases specialist Aurinia Pharmaceuticals on Friday said it has restructured its board of directors. 14 September 2024
US neurological diseases specialist Ovid Therapeutics has announced the promotion of Meg Alexander to president and chief operating officer (COO). 12 September 2024
French pharma company Ipsen today announced that Claude Bertrand, executive vice president, R&D, chief scientific officer, will depart Ipsen on January, 2017, to join another company. 12 December 2016
Lisa Anson, president of AstraZeneca UK and Ireland, has been elected as the next president of trade group the Association of the British Pharmaceutical Industry (ABPI). 7 December 2016
Israel’s Teva Pharmaceutical Industries says that Dipankar Bhattacharjee has been appointed president and chief executive, Global Generic Medicines Group, effective Monday. 6 December 2016
Last week, US biotech major Gilead Sciences terminated its licensing deal with GlobeImmune to develop a hepatitis-B (HBV) drug, GS-4774, and returned rights to the drug. 22 November 2016
Experienced industry executive Hervé Gisserot is to become head of pharmaceuticals for the newly-created Asia Pacific Region at UK pharma major GlaxoSmithKline. 22 November 2016
US biotech major Biogen has named two members to the executive management team of Bioverativ, its planned spin-off company focused on the discovery, research, development and commercialization of treatments for hemophilia and other blood disorders. 16 November 2016
Immuno-oncology company PsiOxus Therapeutics may opt for an initial share offering in 2017, though the company is not looking to go public anytime sooner, chief executive John Beadle told The Pharma Letter in an exclusive interview. 4 November 2016
Roche Pharmaceuticals Asia Pacific says that Dr Christiane Hamacher has assumed the role of head of Asia Pacific (APAC), joining Swiss pharma giant Roche’s global leadership team 1 November 2016
French biotech firm Erytech Pharma today announced the appointments of Dr Alexander Scheer, as the company’s chief scientific officer and Jean-Sébastien Cleiftie, as chief business officer. 27 October 2016
Swiss drug developer EffRx Pharmaceuticals today said it has named Lorenzo Bosisio appointed as chief executive effective July 1st, 2016. 12 October 2016
The board of directors of the Swiss Galenica Group has designated Stefan Schulze, currently chief executive of group company Vifor Fresenius Medical Care Renal Pharma (VFMCRP), as chief operating officer and president of the executive committee of Vifor Pharma. 6 October 2016
Astellas Pharma has appointed Steven Benner as senior vice president and therapeutic area head for oncology, and promoted Anne Keating to vice president of clinical science for oncology, within the company's development organization. 6 October 2016
Santhera Pharmaceuticals has appointed Kristina Timdahl as chief medical officer and head of development and a member of the executive management with effect from January 1, 2017. 5 October 2016
Robert Mulroy, the chief executive of USA-based Merrimack Pharmaceuticals has resigned after 17 years in the role as the company undergoes a major restructuring which will see its workforce cut by 22%. 4 October 2016